Chimeric enters strategic manufacturing partnership with WuXi Advanced Therapies

Chimeric Therapeutics will leverage WuXi Advanced Therapies’ (“WuXi ATU”) closed-loop CAR T platform and other capabilities to accelerate clinical development of its CHM 1101 (CLTX CAR T) and CHM 2101 (CDH17 CAR T) programs for glioblastoma and gastrointestinal cancers, respectively

MELBOURNE, Australia, April 11, 2022 (GLOBE NEWSWIRE) — Chimeric therapy (ASX: CHM, “Chimeric”), a clinical-stage cell therapy company and Australian leader in cell therapy, is pleased to announce that it has entered into a strategic manufacturing partnership with WuXi ATU, a global test and contract manufacturing (CTDMO).

The partnership initially focuses on Chimeric’s two autologous CAR T therapies for solid tumors: CHM 2101 (CDH17 CAR T), currently in late preclinical development for gastrointestinal (GI) cancers, and CHM 1101 (CLTX CAR T), currently being evaluated in a single-site phase 1 clinical trial for patients with recurrent or progressive glioblastoma.

CHM 2101 will build on WuXi ATU’s end-to-end closed-loop CAR T process development, Good Manufacturing Practice (GMP) manufacturing and testing platform, aiming to accelerate development toward its planned first human study.

CHM 1101 will leverage WuXi ATU’s scalable manufacturing and analytical testing capability to enable potential future expansion of the program to multiple additional clinical trial sites and other solid tumor indications, including metastatic melanoma.

“We are thrilled to enter into this partnership with WuXi ATU, said Jennifer Chow, CEO of Chimeric Therapeutics. “With its extensive experience in cGMP manufacturing and analytical testing, as well as its transparent platform process for producing CAR T cells, WuXi ATU is uniquely positioned to support the acceleration and expansion of development programs. CHM 1101 and CHM 2101.”

Dr. David Chang, CEO of WuXi Advanced Therapies, added, “We are delighted to partner with Chimeric Therapeutics to accelerate the development of two of their autologous CAR T cell programs. These treatments offer much-needed hope for patients with gastrointestinal cancers or glioblastoma, and we are honored to support Chimeric Therapeutics as they prepare these treatments for further clinical trials.

This partnership will allow Chimeric to accelerate clinical manufacturing readiness for new CAR T assets and expand CAR T manufacturing to support multiple concurrent, multi-center CAR T clinical trials in the future.


WuXi Advanced Therapies, a global contract assay development and manufacturing organization (CTDMO), is the advanced therapies business unit of WuXi AppTec and provides integrated platforms to transform discovery, development, testing, manufacturing and the commercialization of cell and gene therapies for customers around the world. . WuXi ATU’s technologies, automation platforms and service solutions advance preclinical research and accelerate GMP manufacturing schedule, while integrated GMP manufacturing and testing platforms reduce time to market, maintaining high titers, high levels of quality assurance and full regulatory compliance. Ultimately, WuXi ATU’s comprehensive end-to-end solutions help pioneering companies deliver breakthrough cell and gene therapies to patients in need. For more information, please visit


Chimeric Therapeutics, a clinical-stage cell therapy company and the ASX leader in cell therapy, is focused on realizing the promise of cell therapy for more cancer patients. We believe cell therapies have the promise of curing cancer, not just delaying disease progression.

To realize this promise for more patients, Chimeric’s world-class team of cell therapy pioneers and experts are focused on discovering, developing and commercializing the most innovative and promising cell therapies. .

CHM 1101 (CLTX CAR T) is a new and promising CAR T therapy developed by scientists at the City of Hope Medical Center in California for the treatment of patients with solid tumors. CHM 1101 is currently being studied in a Phase 1 clinical trial in recurrent/progressive glioblastoma. A 2nd Phase 1 CLTX CAR T clinical trial is expected to begin in 2022 in additional solid tumors.

CHM 2101 (CDH17 CAR T) is a new 3rd generation CDH17 CAR T invented at the University of Pennsylvania. CHM 2101 (CDH17 CAR T) is currently in preclinical development with a phase 1 clinical trial planned for 2022 in neuroendocrine tumors, colorectal, pancreatic and gastric cancer.

Chimeric recently announced the addition of the CORE-NK platform, a clinically validated ready-to-use NK (natural killer) cell therapy platform to its portfolio (CHM 0201). From the CORE-NK platform, Chimeric will initiate the development of four new next-generation NK and CAR NK assets with plans for Phase 1 clinical trials to begin in 2023 in solid tumors and blood cancers.

Chimeric Therapeutics continues to actively engage in the development of its oncology pipeline with new cell therapy assets that will realize the promise of cell therapy for more cancer patients.


Jennifer Chow
Chairman and CEO and Managing Director
Chimeric therapy
T: +1 9087238387
Email: [email protected]

Paul Hopper
Executive Chairman
Such. : +61 406 671 515
Email: [email protected]

Matthew Wright
NWR Communications
Such. : +61 451 896 420
Email: [email protected]

main logo

Comments are closed.